Cargando…

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma

Detalles Bibliográficos
Autores principales:	Calabretta, Eleonora, Di Trani, Martina, Sollini, Martina, Ricci, Francesca, Corrado, Francesco, Cristaldi, Vanessa, Bonovas, Stefanos, Marino, Fabrizio, Mazza, Rita, Di Bergamo, Lodovico Terzi, Bruscaggin, Alessio, Pirosa, Maria Cristina, Bramanti, Stefania, Chiti, Arturo, Santoro, Armando, Rossi, Davide, Carlo-Stella, Carmelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Relapsed/Refractory
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621560/ http://dx.doi.org/10.1097/01.HS9.0000891000.99990.30

Ejemplares similares

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
por: Rusconi, Chiara, et al.
Publicado: (2022)

T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
por: Sureda-Balari, Anna, et al.
Publicado: (2022)

P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
por: Viviani, Simonetta, et al.
Publicado: (2022)

P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
por: Moatti, Hannah, et al.
Publicado: (2022)

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
por: Mei, Matthew, et al.
Publicado: (2022)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.
por: Mangasarova, Ya.K., et al.
Publicado: (2022)

P113: Promising results with anti-PD-1 therapy in primary refractory Hodgkin lymphoma: a single-centre report
por: Zerbi, Caterina, et al.
Publicado: (2022)

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
por: Michalka, Jozef, et al.
Publicado: (2022)

P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience
por: Erenmalm, Axel, et al.
Publicado: (2022)

T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
por: Moskowitz, Alison J., et al.
Publicado: (2022)

P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2022)

P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data
por: Driessen, Julia, et al.
Publicado: (2022)

T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
por: Diefenbach, Catherine, et al.
Publicado: (2022)

P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.
por: Kamel, Serageldin, et al.
Publicado: (2022)

Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the “flare phenomenon” to the “abscopal effect”
por: Sollini, Martina, et al.
Publicado: (2021)

Multimodal imaging-based diagnostic approach for MRI-negative posterior cortex epilepsy
por: Mo, Jiajie, et al.
Publicado: (2023)

Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab
por: Bruscaggin, Alessio, et al.
Publicado: (2021)

Chemotherapy after PD‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics
por: Calabretta, Eleonora, et al.
Publicado: (2022)

HTGQC and shinyHTGQC: an R package and shinyR application for quality controls of HTG EDGE-seq protocols
por: Terzi di Bergamo, Lodovico, et al.
Publicado: (2022)

Towards clinical application of image mining: a systematic review on artificial intelligence and radiomics
por: Sollini, Martina, et al.
Publicado: (2019)

Patients’ findings after COVID-19 infection and vaccinations: what to expect from [18F]FDG PET/CT
por: Sollini, Martina, et al.
Publicado: (2021)

Cerebral cavernous malformation remnants after surgery: a single-center series with long-term bleeding risk analysis
por: Fontanella, Marco M., et al.
Publicado: (2020)

Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review
por: Ninatti, Gaia, et al.
Publicado: (2020)

The Role of PET Imaging in the Differential Diagnosis between Radiation Necrosis and Recurrent Disease in Irradiated Adult-Type Diffuse Gliomas: A Systematic Review
por: Ninatti, Gaia, et al.
Publicado: (2023)

Contrast-Enhanced Mammography versus Breast Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis
por: Gelardi, Fabrizia, et al.
Publicado: (2022)

Managing Substance Use Disorder through a Walking/Running Training Program
por: Dai, Chia-Liang, et al.
Publicado: (2020)

COVID-19 vaccination, implications for PET/CT image interpretation and future perspectives
por: Kirienko, Margarita, et al.
Publicado: (2022)

Endoscopic Evacuation of Massive Intraventricular Hemorrhages Reduces Shunt Dependency: A Meta-Analysis
por: Fiorindi, Alessandro, et al.
Publicado: (2022)

Vasculitis changes in COVID-19 survivors with persistent symptoms: an [(18)F]FDG-PET/CT study
por: Sollini, Martina, et al.
Publicado: (2020)

R108
por: CERN PhotoLab
Publicado: (1976)

At R108
por: CERN PhotoLab
Publicado: (1977)

At R108
por: CERN PhotoLab
Publicado: (1977)

At R108
por: CERN PhotoLab
Publicado: (1977)

Methodological framework for radiomics applications in Hodgkin’s lymphoma
por: Sollini, Martina, et al.
Publicado: (2020)

PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome
por: Sollini, Martina, et al.
Publicado: (2019)

The complementary role of PSMA expression and [(18)F]FDG PET/CT in predicting thyroid cancer outcome: from black and white to shades of gray, in the era of precision oncology
por: Sollini, Martina, et al.
Publicado: (2023)

Image Embeddings Extracted from CNNs Outperform Other Transfer Learning Approaches in Classification of Chest Radiographs
por: Gozzi, Noemi, et al.
Publicado: (2022)

Mapping Tumor Heterogeneity via Local Entropy Assessment: Making Biomarkers Visible
por: Costa, Guido, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1p1135hoj4c12qdvs0m27pp0b1